Modulation of gene transcription is one of the ways each cell of an organism can control its gene expression and is achieved through the formation of distinct and transitory protein and/or RNA complexes, which bind to specific DNA sequences, allowing for differential messenger RNA (mRNA) synthesis. It is now clear that a plethora of transcription factors, coregulators and a more limited (as of today) number of regulatory noncoding RNAs assist RNA polymerase II (RNA Pol-II) in mRNA transcription initiation, elongation and/or termination (1–4). Transcriptional coactivators, in particular, regulate the expression of target genes by indirect binding to their target gene promoters and other cis-regulatory elements (such as enhancers and locus control regions), allowing or aiding mRNA transcription (5–7). Coactivators can bind transcription factors or RNA Pol-II augmenting their activities, or helping the recruitment of chromatin modifying enzymes, or acting as chromatin modifiers themselves, with the result of creating a more relaxed chromatin environment, permissive of transcription. In such ways, coactivators act as regulators in multiple processes and are able to generate tissue-, cell- and promoter-specific effects (8–11).
Steroid hormone receptors are members of a superfamily of ligand-dependent transcription factors, and estrogen receptor alpha (ERα, form here on referred to as ER) is one of such receptors (12–14). It is particularly relevant as it is strongly implicated in breast cancer development and progression. Specifically, in estrogen-responsive cells, ER has an important role in regulating proliferation and differentiation and inhibition of ER is a major strategy for the treatment of breast cancers, at least for those that are ER positive (15, 16). Upon estrogen binding, ER undergoes conformational changes: it dimerizes, translocates to the nucleus and binds to specific DNA sequences (called estrogen response elements) through its DNA-binding domain, at specific gene promoters. Finally, through its transactivation domain, ER aids the basal transcriptional machinery (RNA Pol-II and general transcription factors) in the transcription of estrogen responsive genes (17). Thismechanism is common to all steroid hormone receptors. Coregulators (coactivators and corepressors) play a key role in the regulation of steroid receptor transactivation functions. As of today, more than 350 different coregulators have been identified; they form transitory and multiprotein complexes with other coregulators and the hormone receptors and are essential for proper steroid hormone receptor functions (18, 19).
WW-domain binding protein 2 (WBP-2) has been identified, through a functional screen of a cDNA library, as a binding partner of Yes kinase-associated protein (YAP) (20, 21). YAP is a transcriptional regulator and a component of the Hippo pathway that, originally studied in Drosophila and conserved also in mammals, is important for regulation of cell growth, proliferation and tumorigenesis (22, 23). The binding between WBP-2 and YAP occurs through interaction between WW-domains (two in YAP) and PPXY-motifs (three in WBP-2) (24). The WW-domain is a small module that forms a binding pocket for the PPXY-motif; the name refers to two signature tryptophan (W) residues 20–22 amino acids apart in most of the WW-domains. The PPXY-motif (P, proline, X, any amino acid, Y, tyrosine) is a short motif located within a proline-rich domain (21, 25, 26). Through a similar interaction, WBP-2 interacts with TAZ (transcriptional co-activator with PDZ-binding motif) a structurally and functionally similar protein to YAP and also a component of the Hippo pathway (27, 28); with WW-domain containing oxidoreductase 1 (WWOX1), a protein that has been identified as a putative tumor suppressor (29–31); and with Nedd4, an ubiquitin-protein ligase (32). WBP-2 can also interact with proteins that do not contain WW-domains, as in the case of Pax8 (Paired box gene 8), a thyroid-specific transcription factor (33), or E6-associated protein (E6-AP), an E3 ubiquitin ligase and a coactivator of ER (34). In this case, the interaction may not require the PPXY motifs of WBP-2. Despite the identity of some of its binding partners, little is known about the in vivo functions of WBP-2. Some studies indicate that WBP-2 is a downstream component of the Hippo pathway (35), or state its role for the oncogenic properties of TAZ (36), but the precise mechanism by which WBP-2 exerts these functions is still unclear. Our laboratory has previously identified WBP-2 as a bona fide coactivator of ER. Luciferase reporter gene assays demonstrated indeed that WBP-2 enhances ER transactivation activity (34). However, the exact mechanism by which WBP-2 enhances ER functions remains unknown. In this study, we investigate the molecular mechanism underlying WBP-2 coactivation functions. We demonstrate the role of WBP-2 in regulating ER target gene expression and highlight the mechanism by which this occurs. Specifically, WBP-2 enhances ER transactivation function at certain gene promoters by facilitating the recruitment/retention of the histone modifier enzyme p300. This, upon histone acetylation, favors a relaxed chromatin structure, permissive of transcription.
Cell Culture and Reagents
MCF-7 cells were purchased from American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's modified Eagle medium (DMEM) high glucose (Invitrogen, San Diego, CA) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), 100 μg/ml penicillin/streptomycin (Invitrogen), at 37 °C in a humidified 95% air/5% CO2 atmosphere. Cells were proven to be mycoplasma-free by routine testing with Lookout Mycoplasma detection kit (Sigma, St. Louis, MO). Prior to estrogen stimulation, cells were starved for 72 h in phenol-free DMEM high glucose (Invitrogen) with 10% charcoal/dextran-treated fetal bovine serum (Atlanta Biologicals), 100 μg/ml penicillin/streptomycin (Invitrogen). 17β-Estradiol/estrogen (Sigma) was prepared in ethanol and added to the described starvation media for the indicated time at a final concentration of 10−8 M. In this article, the terms hormone and estrogen are used interchangeably.
Plasmid Reverse Transfection
MCF-7 cells were transfected using LipofectamineLTX and Plus reagents (Invitrogen). 4 × 105 cells in complete medium were reverse transfected, in six-well plates, with DNA–Lipofectamine complexes containing 1 μg DNA, 1 μl Plus reagent, 6 μl LipofectamineLTX according to the manufacturer's recommendations. Efficiency of transfection was assessed at every transfection by parallel transfection of a Green Fluorescent Protein (GFP) expressing plasmid. Starvation of the cells was started 16 h post-transfection.
small interfering RNA (siRNA) Reverse Transfection
siRNA was purchased from Dharmacon (Lafayette, CO), as ON-TARGETplus pools: mixtures of four siRNA provided as a single reagent and proven to be both effective and specific in the knockdown. MCF-7 cells were transfected with LipofectamineRNAiMAX reagent (Invitrogen). 6 × 105 cells in complete medium were reverse transfected, in six-well plates, with siRNA–Lipofectamine complexes containing 20 pmol siRNA ON-TARGETplus SMARTpool for hWBP-2 or siRNA ON-TARGETplus nontargeting pool (Dharmacon, cat # L-017572-00-10 and D-00810-10-20, respectively) and 2.5 μl LipofectamineRNAiMAX according to the manufacturer's recommendations. Alternatively, 6 × 106 cells were reverse transfected, in p100 plates, using 100 pmol siRNA ON-TARGETplus SMARTpool for hWBP-2 siRNA ON-TARGETplus nontargeting pool and 12.5 μl LipofectamineRNAiMAX. Starvation of the cells was started 16 h post-transfection.
Total RNA Isolation and Reverse Transcription
Total RNA was isolated from cells grown in six-well plates using the QIAshredder (Qiagen, Valencia, CA), and the RNeasy Mini Kit (Qiagen), following the manufacturer's instructions. 2 μg of total RNA was reverse transcribed using the Maxima First Strand cDNA Synthesis kit (Fermentas, Waltham, MA), according to the manufacturer's protocol but performing the reverse transcription step of the reaction at 55 °C.
Quantitative Polymerase Chain Reaction with cDNA
Each polymerase chain reaction (PCR) was prepared with 25 ng of cDNA, 300 nM forward primer, 300 nM reverse primer, 1× iQ SYBR Green Supermix (Bio-Rad, Hercules, CA)) in a final volume of 10 μl. Reactions were run in triplicates in a LightCycler 480 (Roche, Indianapolis, IN) using the following program: 95 °C, 3 min (4.8 °C/sec); 40 cycles of 95 °C, 10 sec (4.8 °C/sec)—60 °C, 1 min (2.5 °C/sec); melting curve recorded with 95 °C, 1 min (4.8 °C/sec)—55 °C, 1 min (2.5 °C/sec)—95 °C, 0.11 °C/sec (5 acquisitions/sec).
Induction values were calculated with the formula:
according to the Pfaffl method to quantify quantitative PCR (qPCR) results (37) and using 36B4 as the reference gene. Primers used were: 36B4for: 5′-GACAATGGCA GCA TCTAC-3′; 36B4rev: 5′-AAGGTGTAATCCGTCTCC-3′; WBP-2for: 5′-CTGGTC-TGTGCTGGTCTC-3′; WBP-2rev: 5′-AG GGA AGGGAAGGAAGGG-3′; pS2for: 5′-GCGCCCTGGTCCT GGTG TCCAT-3′; pS2rev: 5′-GAAACCACAATTCTGTCTT TC AC-3′; GREB1for: 5′-ATCAGCTGCTCGGACTTGCTG-3′; GR EB1rev: 5′-TGAGCTCCGGTCCTGACAGATG-3′; PRfor: 5′-CC CACAA TACAGCTTCGAGTC-3′; PRrev: 5′-GCGGATTTTA TC AACGA TGCAG-3′.
Cell Lysates Preparation and Western Blot
Cells were washed once with phosphate buffered saline (PBS) and lysed in radio immunoprecipitation assay (RIPA) buffer containing phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor Cocktail (Sigma), as previously described (38). Cell lysates were separated by SDS/PAGE and transferred to nitrocellulose membrane at 100 V for 2 h or 40 mA overnight (ON), at 4 °C. Membranes were blocked with blocking solution (4% non-fat dry milk, 0.1% Tween-20 in PBS) for 1 hour at room temperature (RT) and incubated with the primary antibody (in 3% albumin fraction V (Sigma), 0.1% Tween-20, 0.02% Na-azide in PBS for 2 h at RT, or ON at 4 °C. Primary antibodies used WBP-2 (N-14) (sc-160905, Santa Cruz Biotechnology, Santa Cruz, CA) (1:500) and β-tubulin (ab522339, Abcam, Cambridge, MA)) (1:2,000). After washing three times with the blocking solution, membranes were incubated with appropriate horseradish peroxidase (HRP)-conjugated antibody (anti-goat from Santa Cruz Biotechnology, anti-rabbit from Bio-Rad) (1:4,000) in the blocking solution for 1 h at RT, washed twice with 0.1% Tween-20 in PBS and once with PBS. Protein signals were detected by chemiluminescence, using the SupersignalWest Pico Substrate (Pierce, Rockford, IL) and exposing the membranes to X-ray films. Protein gel images were arranged using Adobe Photoshop 7 and Adobe Illustrator CS softwares.
The buffers used have been previously described (38). Cells grown in p100 plates were fixed with 1% formaldehyde PBS for 10 min, quenched with 125 mM glycine in PBS for 5 min and washed twice in ice-cold PBS for 5 min. Cells were then scraped in ice-cold PBS containing PMSF and protease inhibitor Cocktail, spun and resuspended in lysis buffer with PMSF and protease inhibitor for 20 min rocking, at 4 °C. Nuclear fraction was then collected by centrifuging at 2,655 relative force centrifuge (rcf) at 4 °C and resuspended in 600 μl of shearing buffer with PMSF and protease inhibitor. Chromatin was sheared using a Misonix S-4000 sonicator (Qsonica, Newtown, CT) with a 419 tip, set at 20% amplitude, with 12 pulses of 10 sec each (total energy transferred per sample was ∼650 J, which allows shearing the chromatin into 200–500 base pair fragments). After centrifugation at 20,800 rcf for 12 min at 4 °C, sheared chromatin was used for the IP or stored up to 2 months at −80 °C. 50 μl of the sheared chromatin was kept as input. For the IP, 100 μl of sheared chromatin was diluted 10-fold in buffer Y and precleared with 2 μg of appropriate IgG antibody and 40 μl of salmon sperm DNA/Protein A or G (depending on the antibody isotype) agarose beads (Millipore, Billerica, MA) for 2 h at 4 °C, rocking. Beads were spun at 106 rcf for 1 min at 4 °C, and supernatant was moved to a fresh tube. 2 μg of specific antibody was then used for ON IP at 4 °C, rocking. The day after, salmon sperm DNA/Protein A or G agarose beads were added for 2 h. Beads were washed once in TSEI, once in Tris/Sucrose/Ethylenediaminetetraacetic acid-EDTA (TSE) I, once in TSEIII and twice in Tris/EDTA (TE), 2 min for each wash, rocking. DNA was then eluted in 150 μl of elution buffer, rocking for 20 min, room temperature. Eluted chromatin and input chromatin (50 μl input + 100 μl water) were then reverse crosslinked by adding NaCl to a final concentration of 200 mM and incubating in a water bath, ON at 65 °C. Proteins were removed by bringing samples to a final concentration of 10 mM EDTA and 40 mM Tris pH 6.8 with 1.25 units of Proteinase K for 1.5 h at 45 °C. Finally, DNA was purified using a QIAquick PCR purification kit (Quiagen). The following antibodies were used: WBP2 (ab76680, Abcam), pPol-II (ab5095, Abcam), p300 (sc585, Santa Cruz Biotechnology), acH3K14 (ab52946, Abcam), acH3K9/18 (07-593, Millipore), acH4K8 (07-328, Millipore), acH4K5 (07-327, Millipore).
qPCR for ChIP Samples
Input DNA was diluted five times prior to qPCR. Each reaction was prepared with 5 μl DNA (from input or IPs), 300 nM forward primer, 300 nM reverse primer, 1× iQ SYBR Green Supermix (Bio-Rad) in a final volume of 10 μl. Reactions were run in duplicates or triplicates in a LightCycler 480 (Roche) using the same program described above.
Induction values were calculated with the Plaffl method, normalizing to the inputs and taking into account the nonspecific binding of chromatin to appropriate control IgGs.
Primers used were: pS2ChIPfor: 5′-GGCCATCTCTCACTA TGAATCACTTCTGC-3′; pS2ChIPrev: 5′-GGCAGGCTCTGTTT GCTTAAAGAGCG-3′.
WBP-2 Regulates ER Target Gene Expression
Previous luciferase reporter gene assays from our lab suggest that WBP-2 acts as a coactivator of ER (34). However, the mechanism(s) by which WBP-2 regulates ER target genes is still unknown. To understand the physiological role of WBP-2, we examined the effects of its downregulation or overexpression on ER-mediated gene transcription using MCF-7 breast cancer cells as a model. This cell line was chosen because it is an excellent model to test the effects of estrogen, due to its abundance of ER and reliance on exogenous estrogen for proliferation (39). To determine if WBP-2 is indeed required for maximal ER activation, we knocked down WBP-2 expression in MCF-7 cells by RNA interference. For this purpose, we transfected cells either with WBP-2-specific siRNA (siWBP-2) or with control siRNA (siScrambled) (see Experimental Procedures for details). After estrogen starvation, important to minimize the basal level of estrogen-related effects in the cells, cells were treated with either vehicle (−H) or hormone (+H). WBP-2 knockdown was confirmed both at mRNA level via qPCR and at protein level via Western blot (Figs. 1A and 1B). To determine the effects of WBP-2 knockdown on ER function, we measured the mRNA expression of well-studied estrogen-regulated genes such as pS2 (40), growth regulation by estrogen in breast cancer 1 (GREB1) (41) and progesterone receptor (PR) (42). Notably, WBP-2 knockdown resulted in reduced mRNA levels of the ER target gene pS2 in the presence of hormone, compared to siScrambled transfected cells (Fig. 1C). Similar results were obtained for the mRNA levels of GREB1 (Fig. 1D). However, knockdown of WBP-2 did not have any effect on the mRNA levels of PR (Fig. 1E). As WBP-2 knockdown affects endogenous pS2 and GREB1 mRNA levels, we decided to test whether, on the contrary, WBP-2 overexpression increases the expression of these ER-regulated genes. MCF-7 cells were transfected with either a control plasmid or a plasmid expressing WBP-2. After estrogen starvation, cells were treated with either vehicle (−H) or hormone (+H), and total mRNA was isolated and analyzed focusing on the genes pS2 and GREB1, together with WBP-2 (to confirm overexpression) (Figs. 2A–2C). WBP-2 overexpression had little effect on the transactivation functions of ER in the absence of hormone. However, WBP-2 overexpression significantly enhanced both pS2 and GREB1 expression suggesting that WBP-2 acts as an ER coactivator for pS2 and GREB1 transcription. These data indicate that WBP-2 is required for the complete biological activity of ER in MCF-7 cells.
WBP-2 is Recruited to the pS2 Promoter; Its Presence Correlates with Active Transcription
To substantiate the coactivation function of WBP-2 on ER target gene expression, we used ChIP assays in MCF-7 cells and decided to focus on the pS2 gene, which is a well characterized ER target gene. We wanted to investigate the involvement of WBP-2 in the recruitment of different factors to the pS2 promoter. Hence, we performed ChIP experiments in control cells and in cells in which WBP-2 levels had been knocked down by RNA interference. Previously published data show that ER directs the cyclical recruitment of cofactors on promoters (43, 44). To determine the time point at which to conduct our assays, we conducted pilot time course experiments to evaluate the recruitment of RNA polymerase-II phosphorylated at serine 2 (pPol-II) and various transcription factors and cofactors (ER and p300), at the pS2 promoter at different times after hormone stimulation (data not shown). Forty five minutes of hormone stimulation of the cells correspond, in our hands, to the maximal recruitment of the investigated factors. Therefore, we decided to perform all subsequent ChIP experiments at this time point. MCF-7 cells were treated with either vehicle (−H) or hormone (+H), and chromatin associated with WBP-2 was precipitated using a WBP-2-specific antibody. The precipitated genomic DNA was amplified by qPCR using primer sets specific for the pS2 promoter. ChIP analyses demonstrated the recruitment of WBP-2 onto the pS2 promoter in the presence of estrogen (+H). As expected, upon hormone stimulation, knockdown of WBP-2 is associated with reduction in WBP-2 recruitment at the promoter (Fig. 3A). Unexpectedly, in the absence of hormone, knockdown of WBP-2 is not associated with a significant decrease in its occupancy at the pS2 promoter compared to control cells (siScrambled). This phenomenon, reproducible in different experiments, could be due to a not yet identified feedback mechanism that retains more of this coactivator at the promoter when its cellular levels are very low. Alternatively, it is also possible that a small amount of WBP-2, which is constitutively bound to the promoter of ER target genes, is required for cell survival. Studies are on going to address this point.
We found that WBP-2 binds to pS2 promoter upon estrogen treatment. Additionally, knockdown of WBP-2 in MCF-7 cells resulted in reduced transcription of pS2 upon hormone stimulation (Fig. 1C), and the reduction of pS2 expression correlates with reduced recruitment of WBP-2 (Fig. 3A). Therefore, we decided to explore the mechanism by which WBP-2 strengthens the hormone-dependent functions of ER. Toward this end, we examined the effects of WBP-2 knockdown (performed as described above) on the recruitment of RNA polymerase II phosphorylated on Serine 2 (pPol-II) to the ER target gene promoter pS2. While the presence of RNA polymerase II at a gene promoter indicates an active gene that can therefore be transcribed, the promoter occupancy of pPol-II is associated with a state of productive elongation (45, 46). Upon hormone stimulation, knockdown of WBP-2 resulted in reduced occupancy of pPol-II at the pS2 promoter compared to control cells (siScrambled) (Fig. 3B). These data suggest that WBP-2 acts as a coactivator of ER and is associated with active transcription (as measured by occupancy of pPol-II) at some ER target gene promoters.
WBP-2 Affects the Recruitment of the Chromatin-Modifying Enzyme p300 at Target Gene Promoters
Next we investigated a possible cause for decreased transcription at the pS2 promoter in the context of WBP-2 knockdown. WBP-2 might affect the recruitment of chromatin-modifying enzymes, which regulate the accessibility of chromatin and therefore create an environment permissive for active transcription, exemplified by the observed occupancy of pPol-II. To test this possibility, we performed ChIP assays (as described above) and examined the effects of WBP-2 knockdown on the recruitment of some chromatin modifying enzymes. We decided to focus on p300, because this enzyme has been associated with the initial chromatin modifications that happen at the pS2 promoter to allow transcription, compared to other histone acetyl transferases (43). Under WBP-2 knockdown conditions, the hormone-dependent recruitment of p300 to the pS2 promoter was impaired compared to control cells (siScrambled) (Fig. 4). These data suggest that WBP-2 is required for the recruitment of p300 to the ER target gene promoter pS2, shedding important mechanistic insight into WBP-2's coactivation function.
Specificity of Action in WBP-2-Mediated p300 Recruitment at the pS2 Promoter
p300 is a histone acetyl transferase that promotes an “open” chromatin state by acetylating histones at different lysine residues and therefore promotes/enhances transcription (47). Because WBP-2 is associated with p300 recruitment at the pS2 promoter, we sought to investigate whether WBP-2 is also associated with an open chromatin environment by examining the acetylation status of histones at the pS2 promoter. We performed ChIP assays under WBP-2 knockdown conditions and examined the acetylation status of multiple sites (histone lysine residues) that have been proven to be targets of p300 (48). Knockdown of WBP-2 had no significant effect on the acetylation status of lysine (K) 9 or 18 of histone H3 (H3K9, H3K18), or of lysine 5 or 8 of histone H4 (H4K5 and H4K8) (Figs. 5B–5D). However, knockdown of WBP-2 correlated with a reduction in the acetylation of H3K14 (Fig. 5A). This modification is known to be associated with an active gene status for certain genes and it is the primary acetylation site mediated by p300 (48). Collectively, these data suggest that WBP-2 enhances ER transactivation function at some target genes by facilitating the recruitment and/or the retention of a specific histone-modifying enzyme that favors a relaxed chromatin structure, permissive of transcription.
Coregulators (coactivators and corepressors) play a key role in the regulation of steroid receptor transactivation functions (18, 19) and represent yet another mechanism for tight control of gene expression. In this study, we investigated the coactivation functions of a putative ER coactivator: WBP-2. Previous experiments from our laboratory pointed to WBP-2 as a bona fide coactivator of ER (34). Here, we further investigated WBP-2's coactivation functions and dissected the molecular mechanism of its action.
We demonstrate that WBP-2 is important in regulating certain ER target gene expression. In the past we have noted the specificity in WBP-2's coactivation function for different steroid hormone receptors: indeed, in luciferase gene reporter assays, it seems that WBP-2 can modulate the activity of ER and PR but not of androgen receptor or glucocorticoid receptor (34). Now we also demonstrate specificity regarding WBP-2 action on different ER target genes. More specifically, WBP-2 is required for the full expression of some ER target genes, such as pS2 and GREB1, two well-studied estrogen responsive genes (40, 41) (Figs. 1 and 2). Conversely, WBP-2 levels are not important for the expression of PR, another known estrogen responsive gene (42). Therefore, WBP-2 acts as a selective coactivator of some estrogen responsive genes. As of today we do not know the large-scale (genome-wide) extent of specificity for WBP-2-regulated subsets of ER responsive genes, but the subset specificity provides a general rationale for coactivator function. This is true also for most coactivators: for example, E6 associated protein (49) is an ER coactivator, but it is recruited only to a subset of ER responsive promoters (our unpublished data). Such specificity is also exhibited by the steroid receptor coactivator family (SRC) (50), CBP (51) and p300 (47), among many others. In relation to WBP-2, it is also unknown is if different estrogen responsive genes can be differentially regulated in response to specific stimuli in the cell and the identity of these stimuli. Furthermore, it is uncertain if a group of genes exists that are regulated by WBP-2 independently from ER. This is the case for several steroid hormone receptors (50). Therefore, it would not be surprising to identify WBP-2 as a coactivator also of ER independent genes. Future studies clarifying these possibilities could help in understanding how coactivators in general, and WBP-2 specifically, act in generating tissue-, cell-, receptor- and promoter specific effects (19).
Our present work not only demonstrates WBP-2 has a selective role in ER target gene expression but also sheds light on its mechanism of action. WBP-2 is essential for the full activation of estrogen-induced pS2 expression. In agreement with this, we observed a correlation between WBP-2 levels in the cell and occupancy of phosphoRNA pol-II—associated with a state of productive elongation (45, 46)—at the pS2 promoter (Fig. 3B). WBP-2 seems to act as a coactivator by promoting elongation of RNA pol-II-mediated transcription at ER target gene promoters.
As mentioned above, WBP-2 can bind, through similar interactions, structurally and functionally related proteins YAP and TAZ and WWOX1. YAP and TAZ are both involved in regulation of cell growth, proliferation and tumorigenesis (27), and YAP is a putative ER coactivator (34); WWOX1, on the contrary, is a putative tumor suppressor (31), and our unpublished data show that it also attenuates the transactivation functions of ER. It is intriguing to speculate that WBP-2 might simultaneously regulate the oncogenic activities of YAP and TAZ and the tumor suppressor functions of WWOX1. This possible regulation of oncogenic signaling is particularly relevant for ER, as ER signaling promotes cell proliferation, especially in the context of breast cancer. Through preferential interaction of WBP-2 with YAP or WWOX1, the cell could indeed be pushed more toward proliferation or quiescence, respectively, depending on specific stimuli at specific times. Studies are ongoing in our laboratory to determine this possibility.
The significance of p300 in ER function has long been established (52). This study highlights, for the first time, the importance of yet another component of the ER coactivator complex: WBP-2. We find that WBP-2 can enhance ER transactivation by facilitating the recruitment of p300, an important histone modifier that, upon histone acetylation, favors a relaxed chromatin structure, which permits transcription (36) (Fig. 4). Another possibility is that WBP-2 helps instead the retention of p300 to some target gene promoters. In either case, WBP-2 appears to act as a scaffolding protein, bringing/keeping p300 to the promoter region of a subset of ER target genes. Ongoing studies in our laboratory are investigating the biochemical details of WBP-2 action on p300, with emphasis in discerning between p300 recruitment or maintenance at some ER-responsive promoters.
Together with a prevalent role as histone acetyl transferase, p300 can also act as a transcription factor acetyl transferase, or as a scaffold molecule, for components of the transcription machinery (53). We observed a link between p300 recruitment and specific histones acetylation markers. However, even in this context, p300 might have some additional function.
p300 can acetylate histones at different residues: histone H3 at lysine 14 and lysine 18, as well as histone H4 at lysine 5 and lysine 8 and histone H2B at lysine 12 and lysine 15 (48). We find that WBP-2 is important for one specific p300-dependent histone modification: acetylation of histone H3 on lysine 14, the primary acetylation site mediated by p300 (Fig. 5). This result supports the idea that the fine-tuning of gene expression is achieved by sequential and combinatorial assembly of transcription factors and coregulators at promoters, which control, by modulation of their activity in relation to the specific context they are in, each and every step of gene expression, allowing for tight control on mRNA production. This step-wise knowledge of gene expression in cancer cells not only contributes to our understanding of the basic mechanisms involved in ER signaling but could also provide new future points of intervention for therapeutic purposes.
The authors would like to acknowledge Fernando Cruz-Guilloty and Feng Gong for critically reading the manuscript. This research was supported by the 1R01DK079217-01A2 grant from NIH to Zafar Nawaz.